

# Scott T Tagawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8511197/publications.pdf>

Version: 2024-02-01

206  
papers

13,899  
citations

61945

43  
h-index

22808

112  
g-index

215  
all docs

215  
docs citations

215  
times ranked

14788  
citing authors

#	ARTICLE	IF	CITATIONS
1	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15
2	Pilot study of the diagnostic utility of 89 Zr- $\alpha$ -CB2M and 68 Ga- $\alpha$ -PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer. <i>Prostate</i> , 2022, , .	1.2	8
3	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 430-439.	2.9	15
4	Use of Biosimilar Medications in Oncology. <i>JCO Oncology Practice</i> , 2022, 18, 177-186.	1.4	15
5	Abstract WP198: Hematological And Embolic Biomarkers And Clinical Outcomes In Patients With Cancer And Ischemic Stroke. <i>Stroke</i> , 2022, 53, .	1.0	0
6	Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106297.	0.7	1
7	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 532-532.	0.8	0
8	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of <sup>225</sup> Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 77-77.	0.8	1
9	Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 139-139.	0.8	0
10	Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 96-96.	0.8	1
11	TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS581-TPS581.	0.8	4
12	BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotypeâ€”Phase 2a interim results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 126-126.	0.8	0
13	Quantitative assessment of PSMA imaging before and after <sup>177</sup> Lu-PSMA-617 treatment in a Ph I/II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 37-37.	0.8	0
14	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- <sup>225</sup> Ac-J591 for chemo-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS216-TPS216.	0.8	2
15	TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.. <i>Journal of Clinical Oncology</i> , 2022, 40, 434-434.	0.8	26
16	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. <i>Molecular Oncology</i> , 2022, 16, 2384-2395.	2.1	5
17	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	5.8	3
18	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	6

#	ARTICLE	IF	CITATIONS
19	What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. <i>European Urology Open Science</i> , 2022, 40, 58-94.	0.2	6
20	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. <i>NAR Cancer</i> , 2022, 4, .	1.6	4
21	Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2046-2057.	1.9	8
22	Phase I/II study of <sup>225</sup> Ac-J591 plus <sup>177</sup> Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5100-TPS5100.	0.8	1
23	A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5082-5082.	0.8	3
24	BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5018-5018.	0.8	15
25	Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17007-e17007.	0.8	0
26	Tolerability of [ <sup>177</sup> Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5047-5047.	0.8	1
27	Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4529-4529.	0.8	8
28	Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted <sup>125</sup> I-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 279-285.	1.2	14
29	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2642-2651.	3.3	26
30	Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. <i>Journal of Urology</i> , 2021, 205, 554-560.	0.2	3
31	A phase I/II dose-escalation study of fractionated and multiple dose <sup>225</sup> Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS188-TPS188.	0.8	2
32	Survival outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1032-1040.	2.0	28
33	Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 140-140.	0.8	0
34	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 41-41.	0.8	5
35	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 630589.	1.3	26
36	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 46-46.	0.8	3
38	Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2021, 39, 90-90.	0.8	0
39	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 158-158.	0.8	1
40	Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. <i>Current Oncology Reports</i> , 2021, 23, 59.	1.8	9
41	Abstract P745: Whole Blood MicroRNA and Their Target Messenger RNA Reveal Distinct Transcriptional Changes in Ischemic Stroke Patients With and Without Comorbid Cancer. <i>Stroke</i> , 2021, 52, .	1.0	0
42	Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. <i>European Urology Focus</i> , 2021, 7, 254-257.	1.6	14
43	Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup> Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress. <i>Clinical Cancer Research</i> , 2021, 27, PO-077-PO-077.	3.2	3
44	Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5042-5042.	0.8	4
45	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5095-TPS5095.	0.8	0
46	Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup> Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5087-TPS5087.	0.8	5
47	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5091-TPS5091.	0.8	0
48	Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5055-5055.	0.8	0
49	Phase I study of <sup>225</sup> Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5015-5015.	0.8	24
50	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , 2021, 4, 785.	2.0	3
51	Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. <i>Annals of Neurology</i> , 2021, 90, 159-169.	2.8	31
52	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , 2021, 12, 3372.	5.8	45
53	Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1243-1244.	0.2	0
54	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2474-2485.	0.8	250

#	ARTICLE	IF	CITATIONS
55	A phase I/II study of rovalpituzumab tesirine in delta-like 3 $\alpha$ expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.	2.3	27
56	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	0.8	26
57	Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , 2021, 26, e1971-e1981.	1.9	11
58	Reply to T. Powles et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01673.	0.8	0
59	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 569-576.	0.8	1
60	Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. <i>JAMA Oncology</i> , 2021, 7, 1642.	3.4	3
61	Lutetium-177 $\alpha$ PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	13.9	1,042
62	A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 528-547.	0.8	0
63	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 447-456.	0.9	3
64	Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. <i>Cancer Medicine</i> , 2021, 10, 8570-8580.	1.3	22
65	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology Open Science</i> , 2021, 34, 70-78.	0.2	3
66	NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1383-1389.	1.2	10
67	PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. <i>Prostate</i> , 2020, 80, 99-108.	1.2	45
68	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
69	Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu $\alpha$ J591) for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e9-848.e16.	0.8	29
70	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , 2020, 11, 6195.	5.8	21
71	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
72	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42

#	ARTICLE	IF	CITATIONS
73	CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. <i>Molecular Therapy</i> , 2020, 28, 1238-1250.	3.7	12
74	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1157-1164.	1.9	44
75	An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 863-870.	0.9	7
76	Pilot Study of Hyperfractionated Dosing of Lutetium-177 <sup>â€</sup> Labeled Antiprostata-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2020, 25, 477-e895.	1.9	26
77	Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1736-1743.	0.8	44
78	<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , 2020, 4, 370-381.	1.5	138
79	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1653-1668.	3.9	122
80	Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3055-3055.	0.8	2
81	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3552-3552.	0.8	4
82	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5015-5015.	0.8	17
83	Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5027-5027.	0.8	14
84	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5543-5543.	0.8	17
85	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5560-5560.	0.8	9
86	Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5092-TPS5092.	0.8	4
87	Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5590-TPS5590.	0.8	3
88	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 114-114.	0.8	17
89	Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.. <i>Journal of Clinical Oncology</i> , 2020, 38, 15-15.	0.8	15
90	Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 511-511.	0.8	11

#	ARTICLE	IF	CITATIONS
91	Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2020, 38, e17503-e17503.	0.8	1
92	Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies.. Journal of Clinical Oncology, 2020, 38, 12090-12090.	0.8	0
93	Cell cycle inhibition to target the Evolution of urothelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS5096-TPS5096.	0.8	0
94	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. Journal of Clinical Oncology, 2020, 38, TPS5594-TPS5594.	0.8	0
95	Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).. Journal of Clinical Oncology, 2020, 38, 40-40.	0.8	0
96	Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose <sup>177</sup> Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 45-45.	0.8	1
97	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2019, 381, 338-348.	13.9	885
98	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature Communications, 2019, 10, 2977.	5.8	140
99	Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. Stroke, 2019, 50, 3259-3264.	1.0	10
100	Clinical features of neuroendocrine prostate cancer. European Journal of Cancer, 2019, 121, 7-18.	1.3	195
101	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	24
102	Phase 1/2 study of fractionated dose lutetium- <sup>177</sup> Lu-labeled anti- <sup>177</sup> Lu-PSMA-617 antibody J591 (<sup>177</sup>Lu-PSMA-617) for metastatic castration-resistant prostate cancer. Cancer, 2019, 125, 2561-2569.	2.0	100
103	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine, 2019, 11, .	5.8	105
104	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	0.8	267
105	Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. Journal of Oncology Practice, 2019, 15, 343-345.	2.5	3
106	Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients. Physical Biology, 2019, 16, 036003.	0.8	13
107	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	3.2	177
108	Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood, 2019, 133, 781-789.	0.6	127

#	ARTICLE	IF	CITATIONS
109	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. <i>Clinical Cancer Research</i> , 2019, 25, 1880-1888.	3.2	92
110	Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5013-5013.	0.8	1
111	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 272-272.	0.8	8
112	Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 354-354.	0.8	67
113	TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS495-TPS495.	0.8	3
114	A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS348-TPS348.	0.8	1
115	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018, 73, 687-693.	0.9	99
116	A critical review on ramucirumab in the treatment of advanced urothelial cancer. <i>Future Oncology</i> , 2018, 14, 1049-1061.	1.1	5
117	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , 2018, 78, 775-789.	1.2	35
118	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3251-3258.	0.8	129
119	Antibody-Drug Conjugates in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 247-259.	0.2	29
120	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , 2018, 9, 2404.	5.8	246
121	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA); Tj ETQq1 1 0.784314 rgBT /Overlock 10 T <i>FGFR</i> alterations (FGFRalt).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4503-4503.	0.8	63
122	Upper tract urothelial carcinoma is non-basal and T-cell depleted.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4525-4525.	0.8	1
123	Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with <i>FGFR</i> mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 450-450.	0.8	13
124	Phase I dose-escalation study of <sup>225</sup>Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS399-TPS399.	0.8	20
125	Testosterone (T) suppression by weight and age groups in four pivotal trials of in-situ forming polymer-delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2018, 36, 172-172.	0.8	0
126	Nadir testosterone (T) following in-situ polymer delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2018, 36, 204-204.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, e17039-e17039.	0.8	0
128	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treatment Reviews, 2017, 57, 16-27.	3.4	156
129	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	6.3	153
130	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. Expert Opinion on Biological Therapy, 2017, 17, 135-149.	1.4	5
131	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precision Oncology, 2017, 2017, 1-13.	1.5	30
132	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	0.8	73
133	Trimodality therapy in variant urothelial carcinoma: choose wisely. Translational Andrology and Urology, 2017, 6, 322-325.	0.6	3
134	Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature Genetics, 2016, 48, 1490-1499.	9.4	250
135	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2016, 22, 1510-1519.	3.2	117
136	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305.	15.2	1,193
137	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 1500-1509.	0.8	72
138	Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e75-e79.	0.9	80
139	Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma.. Journal of Clinical Oncology, 2016, 34, 2559-2559.	0.8	2
140	TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5007-5007.	0.8	4
141	Final results of 2-dose fractionation of <sup>177</sup> Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5022-5022.	0.8	6
142	Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing.. Journal of Clinical Oncology, 2016, 34, 354-354.	0.8	3
143	Archexin, a novel AKT-1-specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data.. Journal of Clinical Oncology, 2016, 34, 550-550.	0.8	4
144	Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2016, 34, 379-379.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Fractionated dose radiolabeled anti-PSMA prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 205-205.	0.8	0
146	Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 268-268.	0.8	0
147	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
148	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	3.4	264
149	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical Cancer Research, 2015, 21, 5277-5285.	3.2	163
150	Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, 4513-4513.	0.8	1
151	Defining a molecular subclass of treatment resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5004-5004.	0.8	3
152	A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).. Journal of Clinical Oncology, 2015, 33, 144-144.	0.8	12
153	Fractionated dose radiolabeled anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 194-194.	0.8	2
154	Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.. Journal of Clinical Oncology, 2015, 33, 197-197.	0.8	4
155	Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2015, 33, 295-295.	0.8	7
156	Outcomes of preoperative chemotherapy in bladder cancer patients including node-positive disease.. Journal of Clinical Oncology, 2015, 33, 370-370.	0.8	9
157	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. Journal of Clinical Oncology, 2015, 33, 158-158.	0.8	1
158	Clonal heterogeneity in platinum-resistant metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, 290-290.	0.8	0
159	Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate-specific membrane antigen (PSMA) antibody J591.. Journal of Clinical Oncology, 2015, 33, 164-164.	0.8	0
160	Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count.. Journal of Clinical Oncology, 2015, 33, 199-199.	0.8	0
161	Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate-specific membrane antigen (PSMA) antibody J591.. Journal of Clinical Oncology, 2015, 33, 5054-5054.	0.8	0
162	Use and outcomes of metastasectomy in older patients with urothelial cancers.. Journal of Clinical Oncology, 2015, 33, e15506-e15506.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.. Journal of Clinical Oncology, 2015, 33, 5031-5031.	0.8	1
164	Immunologics and Chemotherapeutics for Renal Cell Carcinoma. Seminars in Interventional Radiology, 2014, 31, 091-097.	0.3	10
165	ERG induces taxane resistance in castration-resistant prostate cancer. Nature Communications, 2014, 5, 5548.	5.8	96
166	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 692-701.	2.0	91
167	Neuroendocrine Prostate Cancer After Hormonal Therapy: Knowing Is Half the Battle. Journal of Clinical Oncology, 2014, 32, 3360-3364.	0.8	29
168	Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5025-5025.	0.8	2
169	Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody <sup>177</sup> Lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5064-5064.	0.8	7
170	Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 204-204.	0.8	5
171	Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 205-205.	0.8	1
172	Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.. Journal of Clinical Oncology, 2014, 32, 25-25.	0.8	3
173	Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2014, 32, 177-177.	0.8	5
174	Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU International, 2013, 111, 44-52.	1.3	67
175	Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal Treatment-Related Neuroendocrine Prostate Cancer. Neoplasia, 2013, 15, 1-1N4.	2.3	205
176	PSMA-targeted dendrimers: a patent evaluation (WO2012078534). Expert Opinion on Therapeutic Patents, 2013, 23, 665-668.	2.4	3
177	Phase II Study of Lutetium-177 Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 5182-5191.	3.2	370
178	Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2013, 3, 214.	1.3	33
179	Noninvasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: A prognostic tool for metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, 11081-11081.	0.8	3
180	A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2013, 31, TPS5096-TPS5096.	0.8	5

#	ARTICLE	IF	CITATIONS
181	TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, TPS5100-TPS5100.	0.8	4
182	Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.. Journal of Clinical Oncology, 2013, 31, 121-121.	0.8	1
183	Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 31-31.	0.8	8
184	Association of CTCAE v4 grading of hypertension with toxicity in patients with renal cancer receiving vascular endothelial growth factor (VEGF)-targeting agents.. Journal of Clinical Oncology, 2013, 31, 447-447.	0.8	3
185	Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow. PLoS ONE, 2013, 8, e85143.	1.1	40
186	Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.. Journal of Clinical Oncology, 2013, 31, e15600-e15600.	0.8	1
187	Prostate-Specific Membrane Antigen-Based Therapeutics. Advances in Urology, 2012, 2012, 1-9.	0.6	74
188	Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer. Journal of Clinical Oncology, 2012, 30, e386-e389.	0.8	185
189	The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer. Prostate Cancer, 2012, 2012, 1-8.	0.4	5
190	Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device. PLoS ONE, 2012, 7, e35976.	1.1	185
191	D-Dimer Levels Among Cancer Patients with Unsuspected Pulmonary Embolism: Clinical Correlates and Relevance. Blood, 2012, 120, 1154-1154.	0.6	2
192	Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy.. Journal of Clinical Oncology, 2012, 30, 100-100.	0.8	3
193	Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).. Journal of Clinical Oncology, 2012, 30, 173-173.	0.8	3
194	Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics.. Journal of Clinical Oncology, 2012, 30, 190-190.	0.8	0
195	Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2012, 30, 120-120.	0.8	0
196	Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. Journal of Clinical Oncology, 2012, 30, 110-110.	0.8	0
197	Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.. Journal of Clinical Oncology, 2012, 30, 4649-4649.	0.8	0
198	Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. Cancer Research, 2011, 71, 6019-6029.	0.4	400

#	ARTICLE	IF	CITATIONS
199	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. <i>Cancer Discovery</i> , 2011, 1, 487-495.	7.7	725
200	PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 29-44.	2.5	84
201	A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 443-448.	0.6	9
202	Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2011, 13, 785-786.	0.8	3
203	Anti-“prostate”-specific membrane antigen-based radioimmunotherapy for prostate cancer. <i>Cancer</i> , 2010, 116, 1075-1083.	2.0	120
204	Primary Squamous Cell Carcinoma of the Urinary Bladder Presenting as Peritoneal Carcinomatosis. <i>Advances in Urology</i> , 2010, 2010, 1-3.	0.6	9
205	Tinzaparin Is Effective and Safe for the Treatment and Extended Secondary Prophylaxis In Cancer Patients with Venous Thromboembolism.. <i>Blood</i> , 2010, 116, 1104-1104.	0.6	1
206	Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. <i>BJU International</i> , 2008, 102, 1086-1091.	1.3	11